ReviewInvestigative and clinical urology2016
Persistence and compliance with medication management in the treatment of overactive bladder.
Review in Investigative and clinical urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Physical and Rehabilitation Therapy for Overactive Bladder in Women: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2023Pooled it
- Pooled it
- Blood pressure increases and other safety and medication compliance in overactive bladder patients treated with SelebetaInvestigative and clinical urology · 2026Observational
- Development of a mobile application for urinary diary monitoring in overactive bladder management.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).Advances in therapy · 2024Observational
- Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study.Neurourology and urodynamics · 2023Observational
- A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder.International neurourology journal · 2023Article
- Correlation between overactive bladder and detrusor overactivity: a retrospective study.International urogynecology journal · 2023Article
- Telemedicine in Overactive Bladder Syndrome.Current bladder dysfunction reports · 2023Review
- Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study.Neurourology and urodynamics · 2023Observational
- What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.Advances in therapy · 2022Article
- Efficacy of non-pharmacological interventions in patients with overactive bladder: A protocol for systematic review and network meta-analysis.Nursing open · 2022Article
- Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms.Frontiers in physiology · 2022Review
- Suppression of Inflammatory and Fibrotic Signals by Cinnamon (Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.Neurourology and urodynamics · 2020Article
- Neuromodulation - a therapeutic option for refractory overactive bladder. A recent literature review.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2019Review
- Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.World journal of urology · 2019Article
- Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care.Advances in therapy · 2019Article
- Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.Lower urinary tract symptoms · 2019Article
- Effects of a combination of herbal extracts (modified Ojayeonjonghwan (Wuzi Yanzong wan)) on partial urethral obstruction-induced detrusor overactivity in rats: impact on the nitric oxide pathway and oxidative stress.BMC complementary and alternative medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overactive bladder (OAB) is a common and chronic condition that impacts patients' daily activities and quality of life. Pharmaco-therapy for OAB is a mainstay of treatment. Antimuscarinics and β3-adrenoceptor agonists are the two major classes of oral pharmacotherapy and have similar efficacy for treating the symptoms of OAB. Owing to the chronic nature of OAB, long-term use of medication is essential for OAB symptom control and positive health outcomes. However, many patients elect to stop their medications during the treatment period. Unmet expectations of treatment and side effects seem to be the major factors for discontinuing OAB pharmacotherapy. Furthermore, the short- and long-term persistence and compliance with medication management are markedly worse in OAB than in other chronic medical conditions. Improvement in persistence and compliance with OAB pharmacotherapy is a hot topic in OAB treatment and should be an important goal in the treatment of OAB. Effective strategies should be identified to improve persistence and compliance. In this review, we outline what is known about persistence and compliance and the factors affecting persistence with pharmacotherapy in patients with OAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.